KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV 주식 보고서

시가총액: US$496.6m

KalVista Pharmaceuticals 소유권

주요 주주는 누구이며 내부자가 매수 또는 매도한 적이 있나요?

최근 내부자 거래

NasdaqGM:KALV 회사 또는 개인의 최근 내부자 거래
날짜가치이름엔티티역할공유최대 가격
05 Nov 24BuyUS$12,000,000Frazier Life Sciences Management, LPCompany1,200,000US$10.00
28 Mar 24SellUS$14,905,154TCG Crossover Management, LLCCompany1,355,014US$11.00
20 Feb 24BuyUS$999,988Frazier Life Sciences Management, LPCompany65,573US$15.25
16 Feb 24SellUS$13,151,726TCG Crossover Management, LLCCompany877,125US$16.22
14 Feb 24SellUS$598,661Christopher YeaIndividual39,886US$15.01
14 Feb 24SellUS$422,827Edward FeenerIndividual28,171US$15.01
14 Feb 24SellUS$875,883Thomas CrockettIndividual58,356US$15.01
14 Feb 24SellUS$613,205Benjamin PalleikoIndividual40,855US$15.01
08 Feb 24BuyUS$1,257,829VR Adviser, LLCCompany86,048US$14.74
30 Jan 24BuyUS$1,274,793VR Adviser, LLCCompany88,099US$14.47
25 Jan 24BuyUS$89,492VR Adviser, LLCCompany7,030US$12.73
24 Jan 24BuyUS$1,241,685VR Adviser, LLCCompany99,129US$12.55
19 Jan 24BuyUS$1,801,602VR Adviser, LLCCompany143,605US$12.60
16 Jan 24BuyUS$333,779VR Adviser, LLCCompany26,246US$12.73
10 Jan 24BuyUS$1,726,457VR Adviser, LLCCompany137,700US$12.67
04 Jan 24BuyUS$720,543VR Adviser, LLCCompany59,369US$12.20
29 Dec 23BuyUS$6,465,650VR Adviser, LLCCompany519,017US$12.50
12 Dec 23BuyUS$2,972,278Frazier Life Sciences Management, LPCompany343,435US$9.53

내부자 거래량

내부자 구매: 내부자가 지난 3개월 동안 판매한 것보다 더 많은 주식을 구입했는지 판단하기에는 데이터가 부족합니다.

소유권 분석

KALV 의 소유 구조는 어떻게 되나요?
소유자 유형공유 수소유권 비율
개인 내부자734,8381.44%
헤지 펀드8,212,00516.1%
VC/PE 기업11,137,59821.8%
교육기관30,987,70160.7%

주식의 희석: 지난 해 주주 수는 희석되었으며, 총 발행 주식 수 43.1% 만큼 증가했습니다.

최대 주주

상위 25 주주가 회사의 93.56%를 소유하고 있습니다.
소유권이름공유현재 값변경 %포트폴리오 %
12.7%
VR Adviser, LLC
6,249,731US$63.1m0%2.93%
9.93%
Frazier Life Sciences Management, LP
4,887,867US$49.3m32.5%1.91%
8.78%
Tang Capital Management, LLC
4,321,547US$43.6m2.43%3.13%
8.56%
Suvretta Capital Management, LLC
4,212,005US$42.5m0.48%1.5%
8.13%
Vestal Point Capital, LP
4,000,000US$40.4m73.9%3.18%
6.86%
Capital Research and Management Company
3,374,064US$34.0m4.54%데이터 없음
6.22%
BlackRock, Inc.
3,062,319US$30.9m3.98%데이터 없음
4.37%
The Vanguard Group, Inc.
2,150,527US$21.7m8.03%데이터 없음
3.23%
Tavistock Life Sciences
1,590,000US$16.0m0%1.0%
3.02%
Emerald Advisers, LLC
1,486,968US$15.0m26.7%0.3%
2.88%
Adage Capital Management, L.P.
1,419,792US$14.3m-30.7%0.02%
2.64%
Great Point Partners, LLC
1,299,503US$13.1m-2.92%4.57%
2.58%
State Street Global Advisors, Inc.
1,271,609US$12.8m68.1%데이터 없음
1.82%
BioImpact Capital LLC
896,915US$9.0m1.7%1.4%
1.69%
Geode Capital Management, LLC
830,984US$8.4m3.07%데이터 없음
1.47%
Dafna Capital Management, LLC
723,678US$7.3m-10.3%1.78%
1.24%
Woodline Partners LP
608,253US$6.1m304%0.05%
1.23%
Dimensional Fund Advisors LP
607,036US$6.1m13.5%데이터 없음
1.17%
Silverarc Capital Management, LLC
574,558US$5.8m2.44%1.31%
1.13%
Saturn V Capital Management LP
556,489US$5.6m-50.7%2.24%
0.88%
Schroder Investment Management Limited
431,232US$4.4m-7.86%데이터 없음
0.78%
Medical Strategy GmbH, Asset Management Arm
382,666US$3.9m0%0.22%
0.77%
Northern Trust Global Investments
379,375US$3.8m14%데이터 없음
0.76%
Jefferies Financial Group Inc.,Asset Management Arm
375,000US$3.8m114%0.18%
0.72%
First Turn Management, LLC
355,000US$3.6m-66.5%0.57%